Functional evaluation of malaria Pfs25 DNA vaccine by in vivo electroporation in olive baboons

Vaccine

Volumn 31, Issue 31, 2013, Pages 3140-3147

  Kumar, Rajesh ^a   Nyakundi, Ruth ^b   Kariuki, Thomas ^b   Ozwara, Hastings ^b   Nyamongo, Onkoba ^b   Mlambo, Godfree ^c   Ellefsen, Barry ^d   Hannaman, Drew ^d   Kumar, Nirbhay ^a  

^a TULANE UNIVERSITY   (United States)

^b INSTITUTE OF PRIMATE RESEARCH   (Kenya)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^d Ichor Medical Systems Inc   (United States)

Author keywords

DNA vaccine; Electroporation; Malaria; Pfs25; Prime boost; Transmission blocking vaccine

Indexed keywords

DNA VACCINE; MALARIA VACCINE; PFS25 DNA VACCINE; PLASMID DNA; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BABOON; CONTROLLED STUDY; DRUG EFFICACY; ELECTROPORATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNITY; IMMUNOGENICITY; MALARIA FALCIPARUM; MOUSE; NONHUMAN; PARASITE TRANSMISSION; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; WESTERN BLOTTING;

ANIMALS; ANTIBODIES, PROTOZOAN; ANTIBODY AFFINITY; ANTIBODY FORMATION; ANTIGENS, PROTOZOAN; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; ELECTROPORATION; FEMALE; IMMUNIZATION, SECONDARY; MALARIA VACCINES; MALARIA, FALCIPARUM; MICE; PAPIO ANUBIS; PLASMIDS; PLASMODIUM FALCIPARUM; PROTOZOAN PROTEINS; RECOMBINANT PROTEINS; VACCINES, DNA;

EID: 84879098059     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.05.006     Document Type: Article

References (41)

1. WHO report 2010: World Health Organization 2010 Global malaria program 2010. Geneva, Switzerland: WHO. http://www.who.int/malaria/publications/atoz/9789241564106/en/index.html.
2. Kumar N. A vaccine to prevent transmission of human malaria: a long way to travel on a dusty and often bumpy road. Curr Sci 2007, 92:1535-1544.
3. Pradel G. Proteins of the malaria parasite sexual stages: expression, function and potential for transmission blocking strategies. Parasitology 2007, 134:1911-1929.
4. Hill A.V. Vaccines against malaria. Philos Trans R Soc Lond B: Biol Sci 2011, 12:2806-2814.
5. Williamson K.C., Keister D.B., Muratova O., Kaslow D.C. Recombinant Pfs230, a Plasmodium falciparum gametocyte protein, induces antisera that reduce the infectivity of Plasmodium falciparum to mosquitoes. Mol Biochem Parasitol 1995, 75:33-42.
6. Outchkourov N.S., Roeffen W., Kaan A., Jansen J., Luty A., Schuiffel D., et al. Correctly folded Pfs48/45 protein of Plasmodium falciparum elicits malaria transmission-blocking immunity in mice. Proc Natl Acad Sci USA 2008, 105:4301-4305.
7. Gozar M.M., Price V.L., Kaslow D.C. Saccharomyces cerevisiae-secreted fusion proteins Pfs25 and Pfs28 elicit potent Plasmodium falciparum transmission-blocking antibodies in mice. Infect Immun 1998, 66:59-64.
8. Chowdhury D.R., Angov E., Kariuki T., Kumar N. A potent malaria transmission blocking vaccine based on codon harmonized full length Pfs48/45 expressed in Escherichia coli. PLoS ONE 2009, 4:e6352.
9. Kaslow D.C., Quakyi I.A., Syin C., Raum M.G., Keister D.B., Coligan J.E., et al. A vaccine candidate from the sexual stage of human malaria that contains EGF-like domains. Nature 1988, 333:74-76.
10. Zou L., Miles A.P., Wang J., Stowers A.W. Expression of malaria transmission-blocking vaccine antigen Pfs25 in Pichia pastoris for use in human clinical trials. Vaccine 2003, 21:1650-1657.
11. Kaslow D.C., Bathurst I.C., Lensen T., Ponnudurai T., Barr P.J., Keister D.B. Saccharomyces cerevisiae recombinant Pfs25 adsorbed to alum elicits antibodies that block transmission of Plasmodium falciparum. Infect Immun 1994, 62:5576-5580.
12. Wu Y., Przysiecki C., Flanagan E., Bello-Irizarry S.N., Ionescu R., Muratova O., et al. Sustained high-titer antibody responses induced by conjugating a malarial vaccine candidate to outer-membrane protein complex. Proc Natl Acad Sci USA 2006, 103:18243-18248.
13. Kubler-Kielb J., Majadly F., Wu Y., Narum D.L., Guo C., Miller L.H., et al. Long-lasting and transmission-blocking activity of antibodies to Plasmodium falciparum elicited in mice by protein conjugates of Pfs25. Proc Natl Acad Sci USA 2007, 104:293-298.
14. Qian F., Rausch K.M., Muratova O., Zhou H., Song G., Diouf A., et al. Addition of CpG ODN to recombinant Pseudomonas aeruginosa ExoProtein A conjugates of AMA1 and Pfs25 greatly increases the number of responders. Vaccine 2008, 26:2521-2527.
15. Wu Y., Ellis R.D., Shaffer D., Fontes E., Malkin E.M., Mahanty S., et al. Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 51. PLoS ONE 2008, 3:e2636.
16. Lobo C.A., Dhar R., Kumar N. Immunization of mice with DNA-based Pfs25 elicits potent malaria transmission-blocking antibodies. Infect Immun 1999, 67:1688-1693.
17. Coban C., Ishii K.J., Stowers A.W., Keister D.B., Klinman D.M., Kumar N. Effect of CpG oligodeoxynucleotides on the immunogenicity of Pfs25, a Plasmodium falciparum transmission-blocking vaccine antigen. Infect Immun 2004, 72:584-588.
18. Coban C., Philipp M.T., Purcell J.E., Keister D.B., Okulate M., Martin D.S., et al. Induction of Plasmodium falciparum transmission-blocking antibodies in nonhuman primates by a combination of DNA and protein immunizations. Infect Immun 2004, 72:253-259.
19. LeBlanc R., Vasquez Y., Hannaman D., Kumar N. Markedly enhanced immunogenicity of a Pfs25 DNA-based malaria transmission-blocking vaccine by in vivo electroporation. Vaccine 2008, 26:185-192.
20. Costa S.M., Paes M.V., Barreto D.F., Pinhao A.T., Barth O.M., Queiroz J.L., et al. Protection against dengue type 2 virus induced in mice immunized with a DNA plasmid encoding the non-structural 1 (NS1) gene fused to the tissue plasminogen activator signal sequence. Vaccine 2006, 24:195-205.
21. Neumann E., Schaefer-Ridder M., Wang Y., Hofschneider P.H. Gene transfer into mouse lyoma cells by electroporation in high electric fields. EMBO J 1982, 1:841-845.
22. Cemazar M., Sersa G. Electrotransfer of therapeutic molecules into tissues. Curr Opin Mol Ther 2007, 9:554-562.
23. Widera G., Austin M., Rabussay D., Goldbeck C., Barnett S.W., Chen M., et al. Increased DNA vaccine delivery and immunogenicity by electroporation in vivo. J Immunol 2000, 164:4635-4640.
24. Bachy M., Boudet F., Bureau M., Girerd-Chambaz Y., Wils P., Scherman D., et al. Electric pulses increase the immunogenicity of an influenza DNA vaccine injected intramuscularly in the mouse. Vaccine 2001, 19:1688-1693.
25. Babiuk S., Baca-Estrada M.E., Foldvari M., Middleton D.M., Rabussay D., Widera G., et al. Increased gene expression and inflammatory cell infiltration caused by electroporation are both important for improving the efficacy of DNA vaccines. J Biotechnol 2004, 110:1-10.
26. Liu J., Kjeken R., Mathiesen I., Barouch D.H. Recruitment of antigen presenting cells to the site of inoculation and augmentation of human immunodeficiency virus type 1 DNA vaccine immunogenicity by in vivo electroporation. J Virol 2008, 82:5643-5649.
27. Ifediba T., Vanderberg J.P. Complete in vitro maturation of Plasmodium falciparum gametocytes. Nature 1981, 294:364-366.
28. Vermeulen A.N., Ponnudurai T., Lensen A.H., Roeffen W.F., Meuwissen J.E. The purification of Plasmodium falciparum macrogametes and/or zygotes prepared from in vitro cultures. Trans R Soc Trop Med Hyg 1983, 77:753-755.
29. Mlambo G., Macial J., Kumar N. Murine model for assessment of Plasmodium falciparum transmission-blocking vaccine using transgenic Plasmodium berghei parasites expressing the target antigen Pfs25. Infect Immun 2008, 76:2018-2024.
30. Malkin E.M., Durbin A.P., Diemert D.J., Sattabongkot J., Wu Y., et al. Phase 1 vaccine trial of Pvs25H: a transmission blocking vaccine for Plasmodium vivax malaria. Vaccine 2004; 2005, 23:3131-3138.
31. Vogel G. The 'do unto others' malaria vaccine. Science 2010, 328:847-848.
32. Kongkasuriyachai D., Bartels-Andrews L., Stowers A., Collins W.E., Sullivan J., Sattabongkot J., et al. Potent immunogenicity of DNA vaccines encoding Plasmodium vivax transmission-blocking vaccine candidates Pvs25 and Pvs28 evaluation of homologous and heterologous antigen-delivery-prime boost strategy. Vaccine 2004, 22:3205-3213.
33. Polack F.P., Lydy S.L., Lee S.H., Rota P.A., Bellini W.J., Adams R.J., Robinson H.L. Poor immune responses of newborn rhesus macaques to measles virus DNA vaccines expressing the hemagglutinin and fusion glycoproteins. Clin Vaccine Immunol 2013, 20:205-210.
34. MacGregor R.R., Boyer J.D., Ugen K.E., Lacy K.E., Gluckman S.J., Bagarazzi M.L., et al. First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: safety and host response. J Infect Dis 1998, 178:92-100.
35. Nyawira T., Gicheru H., Kagasi E., Ng'ang'a Z., Ozwara H. Acute Plasmodium knowlesi infection in olive baboons (Papio anubis) is accompanied by high-level of gamma interferon. Intern J Biol 2012, 4:92-101.
36. D'Hooghe T.M., Kyama C.M., Chai D., Fassbender A., Vodolazkaia A., Bokor A., et al. Nonhuman primate models for translational research in endometriosis. Reprod Sci 2009, 16:152-161.
37. Ozwara H., Langermans J.A., Maamun J., Farah I.O., Yole D.S., Mwenda J.M., et al. Experimental infection of the olive baboon (Paplio anubis) with Plasmodium knowlesi: severe disease accompanied by cerebral involvement. Am J Trop Med Hyg 2003, 69:188-194.
38. Ichagichu M., Ngotho M., Karanja S.M., Kokwaro G., Kariuki T., Nzila A., et al. Preclinical drug evaluation system in the Plasmodium knowlesi baboon model of malaria: the methotrexate study. J Med Primatol 2013, 42:62-70.
39. Sabbatani S., Fiorino S., Manfredi R. The emerging of the fifth malaria parasite (Plasmodium knowlesi): a public health concern?. Braz J Infect Dis 2010, 14(3):299-309. Review.
40. Lee K.S., Divis P.C., Zakaria S.K., Matusop A., Julin R.A., Conway D.J., et al. Plasmodium knowlesi: reservoir hosts and tracking the emergence in humans and macaques. PLoS Pathog 2011, 7:e1002015.
41. Sabbatani S., Fiorino S., Manfredi R. Plasmodium knowlesi: from Malaysia, a novel health care threat. Infez Med 2012, 20:5-11.